Breast-cancer stem cells-beyond semantics

The Lancet Oncology

Volumn 13, Issue 1, 2012, Pages

  Badve, Sunil ^a   Nakshatri, Harikrishna ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALPHA1 INTEGRIN; ALPHA6 INTEGRIN; CD24 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; HERMES ANTIGEN; INTERLEUKIN 6; INTERLEUKIN 8; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN KINASE B; TRANSCRIPTION FACTOR EZH2;

ANGIOGENESIS; BREAST CANCER; CANCER STEM CELL; CELL HETEROGENEITY; CELL ISOLATION; CELL PROLIFERATION; CLONAL ANERGY; DNA REPAIR; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; METASTASIS; NOTE; PHENOTYPE; PHENOTYPIC PLASTICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEMANTICS; STROMA; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ANIMALS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CELL COMMUNICATION; CELL LINEAGE; CELL SURVIVAL; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; PHENOTYPE; PROGNOSIS; SEMANTICS; STROMAL CELLS; TERMINOLOGY AS TOPIC; TUMOR MICROENVIRONMENT;

EID: 84855332744     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70191-7     Document Type: Note

References (68)

1. Clevers H The cancer stem cell: premises, promises and challenges. Nat Med 2011, 17:313-319.
2. Visvader JE, Lindeman GJ Stem cells and cancer-the promise and puzzles. Mol Oncol 2010, 4:369-372.
3. Vassiliou GS, Cooper JL, Rad R, et al. Mutant nucleophosmin and cooperating pathways drive leukemia initiation and progression in mice. Nat Genet 2011, 43:470-475.
4. Dontu G, Abdallah WM, Foley JM, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003, 17:1253-1270.
5. Hussenet T, Dembele D, Martinet N, Vignaud JM, du Manoir S An adult tissue-specific stem cell molecular phenotype is activated in epithelial cancer stem cells and correlated to patient outcome. Cell Cycle 2010, 9:321-327.
6. Raouf A, Zhao Y, To K, et al. Transcriptome analysis of the normal human mammary cell commitment and differentiation process. Cell Stem Cell 2008, 3:109-118.
7. Pece S, Tosoni D, Confalonieri S, et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010, 140:62-73.
8. Youssef KK, Van Keymeulen A, Lapouge G, et al. Identification of the cell lineage at the origin of basal cell carcinoma. Nat Cell Biol 2010, 12:299-305.
9. Lim E, Vaillant F, Wu D, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009, 15:907-913.
10. Proia TA, Keller PJ, Gupta PB, et al. Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate. Cell Stem Cell 2011, 8:149-163.
11. Sircoulomb F, Nicolas N, Ferrari A, et al. ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. EMBO Mol Med 2011, 3:153-166.
12. Shackleton M, Vaillant F, Simpson KJ, et al. Generation of a functional mammary gland from a single stem cell. Nature 2006, 439:84-88.
13. Stingl J, Eirew P, Ricketson I, et al. Purification and unique properties of mammary epithelial stem cells. Nature 2006, 439:993-997.
14. Kendrick H, Regan JL, Magnay FA, et al. Transcriptome analysis of mammary epithelial subpopulations identifies novel determinants of lineage commitment and cell fate. BMC Genomics 2008, 9:591.
15. Creighton CJ, Li X, Landis M, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 2009, 106:13820-13825.
16. Eirew P, Stingl J, Raouf A, et al. A method for quantifying normal human mammary epithelial stem cells with in vivo regenerative ability. Nat Med 2008, 14:1384-1389.
17. Eiraku M, Tohgo A, Ono K, et al. DNER acts as a neuron-specific Notch ligand during Bergmann glial development. Nat Neurosci 2005, 8:873-880.
18. Santos MA, Sarmento LM, Rebelo M, et al. Notch1 engagement by Delta-like-1 promotes differentiation of B lymphocytes to antibody-secreting cells. Proc Natl Acad Sci USA 2007, 104:15454-15459.
19. DiMeo TA, Anderson K, Phadke P, et al. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res 2009, 69:5364-5373.
20. Niessen K, Fu Y, Chang L, Hoodless PA, McFadden D, Karsan A Slug is a direct Notch target required for initiation of cardiac cushion cellularization. J Cell Biol 2008, 182:315-325.
21. Bhat-Nakshatri P, Appaiah H, Ballas C, et al. SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24- phenotype. BMC Cancer 2010, 10:411.
22. Chaffer CL, Brueckmann I, Scheel C, et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci USA 2011, 108:7950-7955.
23. Stephens PJ, Greenman CD, Fu B, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011, 144:27-40.
24. Nakshatri H Radiation resistance in breast cancer: are CD44+/CD24-/proteosome low/PKH26+ cells to blame?. Breast Cancer Res 2010, 12:105.
25. Navin N, Kendall J, Troge J, et al. Tumour evolution inferred by single-cell sequencing. Nature 2011, 472:90-94.
26. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007, 318:1108-1113.
27. Korkaya H, Paulson A, Iovino F, Wicha MS HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 2008, 27:6120-6130.
28. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
29. Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567.
30. Jiang Z, Deng T, Jones R, et al. Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. J Clin Invest 2010, 120:3296-3309.
31. Mizuno H, Spike BT, Wahl GM, Levine AJ Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures. Proc Natl Acad Sci USA 2010, 107:22745-22750.
32. Hanahan D, Weinberg RA The hallmarks of cancer. Cell 2000, 100:57-70.
33. Hanahan D, Weinberg RA Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
34. Kaus A, Widera D, Kassmer S, et al. Neural stem cells adopt tumorigenic properties by constitutively activated NF-kappaB and subsequent VEGF up-regulation. Stem Cells Dev 2010, 19:999-1015.
35. Mani SA, Yang J, Brooks M, et al. Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci USA 2007, 104:10069-10074.
36. Chang CJ, Yang JY, Xia W, et al. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling. Cancer Cell 2011, 19:86-100.
37. Iliopoulos D, Hirsch HA, Struhl K An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009, 139:693-706.
38. Ginestier C, Liu S, Diebel ME, et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 2010, 120:485-497.
39. Criollo A, Senovilla L, Authier H, et al. The IKK complex contributes to the induction of autophagy. EMBO J 2010, 29:619-631.
40. Sheridan C, Kishimoto H, Fuchs RK, et al. CD44+/CD24 breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 2006, 8:59.
41. Korkaya H, Paulson A, Charafe-Jauffret E, et al. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol 2009, 7:1000121.
42. Campbell LL, Polyak K Breast tumor heterogeneity: cancer stem cells or clonal evolution?. Cell Cycle 2007, 6:2332-2338.
43. Fillmore C, Kuperwasser C Human breast cancer stem cell markers CD44 and CD24: enriching for cells with functional properties in mice or in man?. Breast Cancer Res 2007, 9:303.
44. Shackleton M, Quintana E, Fearon ER, Morrison SJ Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 2009, 138:822-829.
45. Hunter K Host genetics influence tumour metastasis. Nat Rev Cancer 2006, 6:141-146.
46. Fillmore CM, Kuperwasser C Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008, 10:25.
47. Honeth G, Bendahl PO, Ringner M, et al. The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res 2008, 10:53.
48. Charafe-Jauffret E, Ginestier C, Iovino F, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009, 69:1302-1313.
49. Resetkova E, Reis-Filho JS, Jain RK, et al. Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res Treat 2010, 123:97-108.
50. Herschkowitz JI, Simin K, Weigman VJ, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007, 8:76.
51. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 2009, 69:4116-4124.
52. Fillmore CM, Gupta PB, Rudnick JA, et al. Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling. Proc Natl Acad Sci USA 2010, 107:21737-21742.
53. Schramek D, Leibbrandt A, Sigl V, et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2010, 468:98-102.
54. Joshi PA, Jackson HW, Beristain AG, et al. Progesterone induces adult mammary stem cell expansion. Nature 2010, 465:803-807.
55. Asselin-Labat ML, Shackleton M, Stingl J, et al. Steroid hormone receptor status of mouse mammary stem cells. J Natl Cancer Inst 2006, 98:1011-1014.
56. Gonzalez-Suarez E, Jacob AP, Jones J, et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 2010, 468:103-107.
57. Tan W, Zhang W, Strasner A, et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 2011, 470:548-553.
58. Brisken C, Duss S Stem cells and the stem cell niche in the breast: an integrated hormonal and developmental perspective. Stem Cell Rev 2007, 3:147-156.
59. Eden JA Breast cancer, stem cells and sex hormones. Part 3: the impact of the menopause and hormone replacement. Maturitas 2011, 68:129-136.
60. Tanos T, Brisken C What signals operate in the mammary niche?. Breast Dis 2008, 29:69-82.
61. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449:557-563.
62. Liu S, Ginestier C, Ou SJ, et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res 2011, 71:614-624.
63. Buess M, Rajski M, Vogel-Durrer BM, Herrmann R, Rochlitz C Tumor-endothelial interaction links the CD44(+)/CD24(-) phenotype with poor prognosis in early-stage breast cancer. Neoplasia 2009, 11:987-1002.
64. Gupta PB, Onder TT, Jiang G, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138:645-659.
65. Hoey T, Yen WC, Axelrod F, et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009, 5:168-177.
66. Marotta LL, Almendro V, Marusyk A, et al. The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24-stem cell-like breast cancer cells in human tumors. J Clin Invest 2011, 121:2723-2735.
67. Hayes DF, Bast RC, Desch CE, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996, 88:1456-1466.
68. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25:5287-5312.